NCI

Early sub-protocol results presented at AACR meeting hint at better outcomes for Mektovi-treated cases with NRAS codon 61 tumor mutations.

Anetumab ravtansine was well tolerated and there was "a positive trend" suggesting that high mesothelin expression may indicate which cancer patients benefit from BAY 94-9343.

The authors of the study noted that these genetic findings could guide better clinical decisions for patients and improve outcomes.

The finding suggests that African-American patients may be more likely to respond to treatment with poly ADP ribose polymerase (PARP) inhibitors.

Lantern will use its AI platforms and NCI's omics datasets to identify and validate predictive genomic signatures for drugs it is developing.

Funded projects will look at the combination of imaging and liquid biopsies for monitoring cancer patient responses and the emergence of treatment resistance.

The software firm will use NGS data from patient biopsies to create molecular profiles and offer individualized cancer treatment recommendations.